Research progress of obesity and colorectal cancer

doi:10.3877/cma.j.issn.2095-9605.2024.02.008

Abstract

Abstract:

Obesity can not only cause metabolic diseases such as diabetes and hyperlipidemia, but also promote the occurrence of tumors. There are many common risk factors between obesity and colorectal cancer. More and more studies have shown that obesity is involved in the occurrence and development of colorectal cancer, but the mechanism of action has not been fully clarified. In addition, the development of metabolic and bariatric surgery and drugs is affecting the treatment of obesity-related tumors. This article reviews the relationship, mechanism, treatment and prevention of obesity and colorectal cancer.

Key words: Obesity, Colorectal cancer, Risk factor, Prevention, Metabolic and bariatric surgery

Jianbin Zhuang, Mingjian Yang. Research progress of obesity and colorectal cancer[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2024, 10(02): 120-126.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2024.02.008

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2024/V10/I02/120

Figures/Tables 1

References 58

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Piché ME, Tchernof A, Després JP, et al. Obesity phenotypes, diabetes, and cardiovascular diseases [J]. Circ Res, 2020, 126(11): 1477-1500.
[3]	Brown KF, Rumgay H, Dunlop C, et al. The fraction of cancer attributable to modifiable risk factors in england, wales, scotland, northern Ireland, and the united kingdom in 2015 [J]. Br J Cancer, 2018, 118(8): 1130-1141.
[4]	Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature [J]. BMJ, 2017, 356: j477.
[5]	Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report [J]. Diabetes Care, 2010, 33(7): 1674-1685.
[6]	Park SW, Lee HL, Doo EY, et al. Visceral obesity predicts fewer lymph node metastases and better overall survival in colon cancer [J]. J Gastrointest Surg, 2015, 19(8): 1513-1521.
[7]	Abar L, Vieira AR, Aune D, et al. Height and body fatness and colorectal cancer risk: an update of the WCRF-AICR systematic review of published prospective studies [J]. Eur J Nutr, 2018, 57(5): 1701-1720.
[8]	Spychalski P, Kobiela J, Wieszczy P, et al. Clinical stages of colorectal cancer diagnosed in obese and overweight individuals in the Polish Colonoscopy Screening Program [J]. United European Gastroenterol J, 2019, 7(6): 790-797.
[9]	Li H, Yang G, Xiang YB, et al. Body weight, fat distribution and colorectal cancer risk: a report from cohort studies of 134255 Chinese men and women [J]. Int J Obes (Lond), 2013, 37(6): 783-789.
[10]	Mandic M, Safizadeh F, Niedermaier T, et al. Association of overweight, obesity, and recent weight loss with colorectal cancer risk [J]. JAMA Netw Open, 2023, 6(4): 239-556.
[11]	Low EE, Demb J, Liu L, et al. Risk factors for early-onset colorectal cancer [J]. Gastroenterology, 2020, 159(2): 492-501.
[12]	Lennon H, Sperrin M, Badrick E, et al. The obesity paradox in cancer: a Review [J]. Curr Oncol Rep, 2016, 18(9): 56.
[13]	Sedlak JC, Yilmaz ÖH, Roper J, et al. Metabolism and colorectal cancer [J]. Annu Rev Pathol, 2023, 18: 467-492.
[14]	Farinetti A, Zurlo V, Manenti A, et al. Mediterranean diet and colorectal cancer: A systematic review [J]. Nutrition, 2017, 43-44: 83-88.
[15]	Xu P, Li J, Liu J, et al. Mature adipocytes observed to undergo reproliferation and polyploidy [J]. FEBS Open Bio, 2017, 7(5): 652-658.
[16]	Ko JH, Um JY, Lee SG, et al. Conditioned media from adipocytes promote proliferation, migration, and invasion in melanoma and colorectal cancer cells [J]. J Cell Physiol, 2019,234(10): 18249-18261.
[17]	Wang Q, Su Y, Sun R, et al. MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning [J]. Cell Biosci, 2024, 14(1): 12.
[18]	Ye P, Xi Y, Huang Z, et al. Linking obesity with colorectal cancer: epidemiology and mechanistic insights [J]. Cancers (Basel), 2020, 12(6): 1408.
[19]	Schumacher N, Rose-John S. ADAM17 activity and IL-6 trans-signaling in inflammation and cancer [J]. Cancers (Basel), 2019, 11(11): 1736.
[20]	Rodrigues KF, Pietrani NT, Bosco AA, et al. IL-6, TNF-α, and IL-10 levels/polymorphisms and their association with type 2 diabetes mellitus and obesity in Brazilian individuals [J]. Arch Endocrinol Metab, 2017, 61(5): 438-446.
[21]	Bou Malhab LJ, Abdel-Rahman WM. Obesity and inflammation: colorectal cancer engines [J]. Curr Mol Pharmacol, 2022, 15(4): 620-646.
[22]	Wang L, Chen L, Liu Z, et al. PAI-1 Exacerbates white adipose tissue dysfunction and metabolic dysregulation in high fat diet-Induced obesity [J]. Front Pharmacol, 2018, 9: 1087.
[23]	Chen H, Peng H, Liu W, et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis [J]. Surgery, 2015, 158(6): 1704-1713.
[24]	Lee CJ, Sears CL, Maruthur N. Gut microbiome and its role in obesity and insulin resistance [J]. Ann N Y Acad Sci, 2020, 1461(1): 37-52.
[25]	Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer [J]. Nat Rev Gastroenterol Hepatol, 2018, 15(11): 671-682.
[26]	Mizutani S, Yamada T, Yachida S. Significance of the gut microbiome in multistep colorectal carcinogenesis [J]. Cancer Sci, 2020, 111(3): 766-773.
[27]	Jia W, Rajani C, Xu H, et al. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma [J]. Protein Cell, 2021, 12(5): 374-393.
[28]	Shuwen H, Miao D, Quan Q, et al. Protective effect of the "food-microorganism-SCFAs" axis on colorectal cancer: from basic research to practical application [J]. J Cancer Res Clin Oncol, 2019, 145(9): 2169-2197.
[29]	Chávez-Talavera O, Tailleux A, Lefebvre P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease [J]. Gastroenterology, 2017, 152(7): 1679-1694.
[30]	Nguyen TT, Ung TT, Kim NH, et al. Role of bile acids in colon carcinogenesis [J]. World J Clin Cases, 2018, 6(13): 577-588.
[31]	Fu T, Coulter S, Yoshihara E, et al. FXR regulates intestinal cancer stem cell proliferation [J]. Cell, 2019, 176(5): 1098-1112.
[32]	Vigneri PG, Tirrò E, Pennisi MS, et al. The insulin/IGF system in colorectal cancer development and resistance to therapy [J]. Front Oncol, 2015, 5: 230.
[33]	Cheraghpour M, Askari M, Tierling S, et al. A systematic review and meta-analysis for the association of the insulin-like growth factor1 pathway genetic polymorphisms with colorectal cancer susceptibility [J]. Front Oncol, 2023, 13: 1168942.
[34]	Tognon CE, Sorensen PH. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy [J]. Expert Opin Ther Targets, 2012, 16(1): 33-48.
[35]	Xie Q, Chu Y, Yuan W, et al. Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer through triggering the MEX3A-mediated degradation of RIG-I [J]. Acta Pharm Sin B, 2023, 13(7): 2963-2975.
[36]	Alrashid MH, Al-Serri AE, Hussain RF, et al. Association study of IGF-1 rs35767 and rs6214 gene polymorphisms with cancer susceptibility and circulating levels of IGF-1, IGFBP-2, and IGFBP-3 in colorectal cancer patients [J]. Biomedicines, 2023, 11(12): 3166.
[37]	Modzelewska P, Chludzińska S, Lewko J, et al. The influence of leptin on the process of carcinogenesis [J]. Contemp Oncol (Pozn), 2019, 23(2): 63-68.
[38]	Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction [J]. Int J Mol Sci, 2017, 18(6): 1321.
[39]	Wang Y, Li J, Fu X, et al. Association of circulating leptin and adiponectin levels with colorectal cancer risk: A systematic review and meta-analysis of case-control studies [J]. Cancer Epidemiol, 2021, 73: 101958.
[40]	Saxena A, Baliga MS, Ponemone V, et al. Mucus and adiponectin deficiency: role in chronic inflammation-induced colon cancer [J]. Int J Colorectal Dis, 2013, 28(9): 1267-1279.
[41]	Otani K, Ishihara S, Yamaguchi H, et al. Adiponectin and colorectal cancer [J]. Surg Today, 2017, 47(2): 151-158.
[42]	Duraiyarasan S, Adefuye M, Manjunatha N, et al. Colon cancer and obesity: a narrative review [J]. Cureus, 2022, 14(8): e27589.
[43]	Yang G, Fan W, Luo B, et al. Circulating resistin levels and risk of colorectal cancer: a meta-analysis [J]. Biomed Res Int, 2016, 2016: 7367485.
[44]	Tarkowski A, Bjersing J, Shestakov A, et al. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4 [J]. J Cell Mol Med, 2010, 14(6B): 1419-1431.
[45]	Hourdequin KC, Schpero WL, McKenna DR, et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis [J]. Ann Oncol, 2013, 24(12): 2952-2962.
[46]	Makino T, Shukla PJ, Rubino F, et al. The impact of obesity on perioperative outcomes after laparoscopic colorectal resection [J]. Ann Surg, 2012, 255(2): 228-236.
[47]	Tsukamoto S, Nishizawa Y, Ochiai H, et al. Surgical outcomes of robot-assisted rectal cancer surgery using the da Vinci Surgical System: a multi-center pilot PhaseⅡstudy [J]. Jpn J Clin Oncol, 2017, 47(12): 1135-1140.
[48]	Marrone MT, Mondul AM, Prizment AE, et al. Lipid-lowering drug use and cancer incidence and mortality in the ARIC study [J]. JNCI Cancer Spectr, 2021, 5(5): pkab080.
[49]	Huang X, Sun T, Wang J, et al. Metformin reprograms tryptophan metabolism to stimulate CD8+ T-cell function in colorectal cancer [J]. Cancer Res, 2023, 83(14): 2358-2371.
[50]	Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists [J]. Pharmacol Res, 2022, 182: 106320.
[51]	Alalwan AA, Friedman J, Park H, et al. US national trends in bariatric surgery: A decade of study [J]. Surgery, 2021, 170(1): 13-17.
[52]	Krishnan A, Hadi Y, Alqahtani SA, et al. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity [J]. JAMA Netw Open, 2023, 6(4): e237188.
[53]	Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies [J]. Lancet, 2008, 371(9612): 569-578.
[54]	Ghiassi S, El Chaar M, Aleassa EM, et al. ASMBS position statement on the relationship between obesity and cancer, and the role of bariatric surgery: risk, timing of treatment, effects on disease biology, and qualification for surgery [J]. Surg Obes Relat Dis, 2020, 16(6): 713-724.
[55]	Afshar S, Malcomson F, Kelly SB, et al. Biomarkers of colorectal cancer risk decrease 6 months after roux-en-y gastric bypass surgery [J]. Obes Surg, 2018, 28(4): 945-954.
[56]	Chierici A, Amoretti P, Drai C, et al. Does bariatric surgery reduce the risk of colorectal cancer in individuals with morbid obesity? a systematic review and meta-analysis [J]. Nutrients, 2023, 15(2): 467.
[57]	Mackenzie H, Markar SR, Askari A, et al. Obesity surgery and risk of cancer [J]. Br J Surg, 2018, 105(12): 1650-1657.
[58]	Pararas N, Pikouli A, Dellaportas D, et al. The protective effect of bariatric surgery on the development of colorectal cancer: a systematic review and meta-analysis [J]. Int J Environ Res Public Health, 2023, 20(5): 3981.

Please choose a citation manager

Content to export